Drug intelligence / Profile preview

ARM1

Development stage: Preclinical
Modality: Small Molecules

Overview

ARM1, also known as 4-(4-benzylphenyl) thiazol-2-amine, is a small molecule that functions as a selective inhibitor of the epoxide hydrolase activity of leukotriene A4 hydrolase (LTA4H). LTA4H is a key enzyme in the 5-lipoxygenase pathway, responsible for converting leukotriene A4 to the inflammatory mediator leukotriene B4 (LTB4). By inhibiting LTA4H's epoxide hydrolase activity, ARM1 aims to block LTB4 production and reduce inflammation. Preclinical studies have shown its ability to reduce LTB4 levels in a murine bacterial pneumonia model.

Other names: 4-(4-benzylphenyl) thiazol-2-amine

Targets

LTA4H (Leukotriene A4 hydrolase)

Beyond the preview

Go deeper on ARM1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARM1.

Explore the full profile